A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity
Final published version, 1.16 MB, PDF document
Original language | English |
---|---|
Journal | Acta Neuropathologica |
Volume | 138 |
Issue number | 2 |
Pages (from-to) | 237-250 |
Number of pages | 14 |
ISSN | 0001-6322 |
DOIs | |
Publication status | Published - 2019 |
Bibliographical note
Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. DOI: 10.1007/s00401-019-02026-8
- Alzheimer's disease, Frontotemporal dementia, Dementia with Lewy bodies, Progressive supranuclear palsy, Parkinson's disease, Amyotrophic lateral sclerosis, Multiple sclerosis, Neurodegenerative disease, Longevity, PLCG2, Phospholipase C Gamma 2
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
No data available
ID: 225518896